Lumida
/PCRX
⌘K
Pacira Biosciences Inc

Pacira Biosciences Inc

PCRX
$25.36USD↑+0.79%+0.20 today

MARKET CAP

1.0B

P/E (TTM)

211.3x

FWD P/E

—

DAY RANGE

$25 – $26

52W RANGE

$19
$28

AI Summary

Stalk
Buy NowMedium

PCRX remains in a Stage 2 advance with an active Momentum Breakout clearing the consolidation high, and EMAs aligned bullishly. Price is tracking above rising 9/20/50 EMAs with RSI supportive, validating near-term participation. Execution favors buying shallow pullbacks into the 20-day EMA near recent support. Primary risks include overhead resistance at the prior swing high and a decisive close below the 50-day SMA.

  • ↑Q2 revenue reached $192.4 M (+6% YoY) with adjusted EBITDA of $48.7 M
  • ↑Exparel now covers over 150 M lives, widening U.S. market access
  • ↓Elective surgery volumes sensitive to macroeconomic swings, slowing growth
Full analysis →

Buying

5

institutions

Selling

6

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

SELL6.71 M170.13 M+-29.53 K+11.8%0.00%
RT

Renaissance Technologies LLC

Q2 2026

SELL1.73 M43.99 M+-91.70 K+6.6%0.06%
JC

Jpmorgan Chase & Co

Q2 2026

BUY346.70 K8.70 M+106.33 K+55.5%0.00%
MM

Millennium Management LLC

Q2 2026

BUY235.16 K5.97 M+178.13 K+362.9%0.00%
CA

Citadel Advisors LLC

Q2 2026

SELL162.16 K4.11 M+-635.12 K-77.2%0.00%
AC

Aqr Capital Management LLC

Q2 2026

BUY158.51 K4.02 M+4.21 K+15.3%0.00%
MG

Man Group Plc

Q2 2026

BUYNEW125.37 K3.18 M+125.37 K+0.0%0.01%
JH

Janus Henderson Group Plc

Q1 2026

BUY46.64 K1.05 M+23.32 K+74.7%0.00%
RC

Rockefeller Capital Management L.P.

Q2 2026

SELL1.08 K27.35 K+-465.00-21.6%0.00%
BA

Balyasny Asset Management L.P.

Q2 2026

SELL0.000.00+-106.42 K-100.0%0.00%
VI

Voloridge Investment Management, LLC

Q2 2026

SELL0.000.00+-19.76 K-100.0%0.00%